European Heart Journal Advance Access published online on November 25, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn516
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term benefit–risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
1 Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
2 Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
3 Bruderholzspital, Bruderholz, Switzerland
Received 16 June 2008; revised 29 September 2008; accepted 23 October 2008.
* Corresponding author. Tel: +41 265 5214, Fax: +41 265 4598, Email: pfisterer{at}email.ch
Aims: To assess the long-term benefit–risk ratio of drug-eluting (DES) vs. bare-metal stents (BMS) relative to stent size.
Methods and results: All 826 consecutive BASKET (BAsel Stent Kosten-Effektivitäts Trial) patients randomized 2:1 to DES vs. BMS were followed after 3 years. Data were analysed separately for patients with small stents (<3.0 mm vessel/<4.0 mm bypass grafts, n = 268) vs. only large stents (
3.0 mm native vessels, n = 558). Clinical events were related to stent thrombosis. Three-year clinical target-vessel revascularization rates remained borderline reduced after DES [9.9 vs. 13.9% (BMS), P = 0.07], particularly in patients with small stents (10.7 vs. 19.8%, P = 0.03; large stents: 9.5 vs. 11.5%, P = 0.44). Cardiac death/myocardial infarction (MI) rates (12.7 vs. 10.0%, P = 0.30) were similar, however, death/MI beyond 6 months was higher after DES [9.1 vs. 3.8% (BMS), P = 0.009], mainly due to increased late death/MI in patients with large stents (9.7 vs. 3.1%, P = 0.006). The results paralleled findings for stent thrombosis.
Conclusion: The clinical benefit of DES was maintained at no overall increased risk of death or death/MI up to 3 years. However, death/MI rates were increased in DES vs. BMS patients beyond 6 months, particularly in patients with large stents, paralleling findings for stent thrombosis. Thus, stent size seems to influence the 3-year benefit–risk ratio after DES implantation.
Key Words: Drug-eluting stents • Bare-metal stents • Stent thrombosis • Outcome • Coronary artery disease
The first two authors contributed equally to this paper.
The BAsel Stent Kosten-Effektivitäts Trial (BASKET) Investigators are listed in Ref. 14.
Trial Registration number: ISRCTN75663024 [controlled-trials.com] – BAsel Stent Kosten-Effektivitäts Trial (Basel stent cost-effectiveness trial).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study Eur. Heart J., September 1, 2009; 30(17): 2095 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Wykrzykowska, P. W. Serruys, Y. Onuma, T. de Vries, G.-A. van Es, P. Buszman, A. Linke, T. Ischinger, V. Klauss, R. Corti, et al. Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer: The LEADERS Trial Substudy J. Am. Coll. Cardiol. Intv., September 1, 2009; 2(9): 861 - 870. [Abstract] [Full Text] [PDF]
|
|